Augmentation of experimental skin flap survival via postoperative phosphocreatine replacement.
Despite improvements in our understanding of cutaneous vascular territories, clinical skin flap necrosis resulting from ischemic compromise is still a reality. Therapy with vasodilators has been generally unsuccessful, but replacement of high-energy phosphometabolites through the use of ATP-MgCl2 and fructose 1,6-diphosphate has been effective. Recently we reported that phosphocreatine is the major high-energy phosphometabolite in mammalian skin and that ATP levels and cellular well-being in skin flaps are dependent on adequate supply of this phosphometabolite. We report herein the successful augmentation of survival of ischemically compromised skin flaps through postoperative phosphocreatine infusion. This metabolite effectively circumvents the nonfunctioning mitochondrial creatine-phosphocreatine energy shuttle without disturbing the delicate [ATP]/[ADP] balance in the cytosol. In addition, phosphocreatine may favorably redistribute blood flow from muscle to the ischemically compromised skin.
Cuono
C B
CB
Cortes
A
A
Marquetand
R
R
Weisberg
V
V
Armitage
I M
IM
D000818:Animals; D004355:Drug Stability; D006085:Graft Survival / Q000187:drug effects*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D010725:Phosphocreatine / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology*; D011182:Postoperative Care; D051381:Rats; D011919:Rats, Inbred Strains; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply / Q000378:metabolism; D016038:Skin Transplantation; D013524:Surgical Flaps
D010725:Phosphocreatine